• Immunomodulator Platform
• Stradomer^TM Platform
• Stradomer^TM-coated Device Platform
• Stradobody^TM Platform

The Stradomer^TM Platform

GL-2045 is Gliknik's lead recombinant stradomer^TM for autoimmune diseases. It has demonstrated potent efficacy in animal models of arthritis, organ transplant, inflammation, and autoimmune disease. GL-2045 is one of many active compounds from the stradomer^TM platform, a series of recombinant compounds designed to compete with intravenous immunoglobulin (IVIG) and antibody therapies used in immune disorders such as rheumatoid arthritis. IVIG is a $3 Billion product pooled from tens of thousands of donors and used in many autoimmune and inflammatory diseases that are characterized by autoantibodies and hyperaggressive T cells. Despite its commercial success and usefulness in patients, IVIG has numerous drawbacks including high cost, scarce supply, potentially serious reactions, extended infusion time, and a persistent concern about infectious risks.